Upadacitinib
Upadacitinib has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. It is an approved medicine. The newest paper, Feb 10, 2026: “The Impact of PRAC EMA/AIFA Recommendations on the Prescriptions of JAKi and b-DMARDs: Preliminary Results of the Survey from 21 Rheumatological Italian Centers Affiliated with CReI”.
1 paper studies it1 findingUpdated
See all 1 papers on upadacitinib
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country; 96 trials, none about aging, 4 with no results posted.
- 1 lab in 1 country
- 96 trials, none about aging, 4 with no results posted
- 65 of 96 trials sponsored by its developers
- Humans1
What acts on upadacitinib?
1Studies name prac recommendations as acting on upadacitinib.
Prac recommendations
no changein humans1
1 study
Prac recommendations
no changein humans1
Prac recommendations were not clearly linked with upadacitinib in humans (rheumatoid arthritis).
“Notably, upadacitinib utilization remained stable despite regulatory restrictions.”
Humansrheumatoid arthritis
Journal of personalized medicine
Has upadacitinib been tested in people?
0 of 96 about agingYes: 1 observational study in people have been published, and 95 trials are registered.
Approved
Aug 16, 2019Active Rheumatoid Arthritis
Dec 16, 2019Arthritis, Rheumatoid, Arthritis, Psoriatic, Axial Spondyloarthritis, Spondylitis, Ankylosing, Giant Cell Arteritis, Dermatitis, Atopic, Colitis, Ulcerative, Crohn Disease, Alopecia Areata, Vitiligo, Non-Segmental Vitiligo, Severe Alopecia Areata, polyarticular juvenile idiopathic arthritis, Active Rheumatoid Arthritis, Moderate-to-Severe Atopic Dermatitis, non radiographic axial spondyloarthritis, moderately to severely active ulcerative colitis
Apr 26, 2024Active Rheumatoid Arthritis
Repurposing
Phase 3Recruiting1 trial
Phase 3Results posted7 trials
Phase 3Results posted7 trials
Phase 3Active, not recruiting4 trials
Phase 3Results posted2 trials
Phase 3Results posted7 trials
All 21Fewer
In trials
Acute Severe Ulcerative Colitis
Phase 4Recruiting2 trials
Ulcerative colitis acute
Phase 4Recruiting2 trials
Readouts due
- Nov 2026
- Dec 2026
Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study
Phase 3Recruiting
- Dec 2026
- Jan 2027
- Mar 2027
- Jun 8, 2027
All 8Fewer
Stopped
NCT06773403TerminatedPrurigo nodularis
There was not a big enough patient population to meet recruitment goals
Who is developing upadacitinib?
3 companies: AbbVie, Rheinische Friedrich-Wilhelms-Universitaet Bonn and Takeda.
Trial sponsors
Company55 trialsPhase 427,356 people
Company2 trialsPhase 4300 people
Company1 trialPhase 3396 people
Rheinische Friedrich-Wilhelms-Universität Bonn
Company1 trialPhase 370 people
Sixth Affiliated Hospital, Sun Yat-sen University
4 trialsPhase 41,007 people
University of California, San Francisco
2 trialsPhase 460 people
1 trialPhase 4308 people
Xijing Hospital of Digestive Diseases
1 trialPhase 4226 people